Prostate-Specific Antigen (PSA) Guidelines

Definition and Normal Ranges

The American Urological Association defines an elevated Prostate-Specific Antigen (PSA) as a serum level above 4.0 ng/mL, which warrants further investigation due to increased risk of prostate cancer, though age-specific reference ranges and other factors must be considered in clinical interpretation 1
PSA is a serum glycoprotein produced by the prostate gland that serves as a widely used tumor marker for prostate cancer 2
Traditional threshold for an elevated PSA is >4.0 ng/mL, which has been the standard indication for prostate biopsy since the 1980s 2
Age-specific reference ranges have been established to account for natural PSA increases with age 40-49 years: 0-2.5 ng/mL for whites, 0-2.0 ng/mL for African-Americans and Asian-Americans 1
- 50-59 years: 0-3.5 ng/mL for whites, 0-4.0 ng/mL for African-Americans, 0-3.0 ng/mL for Asian-Americans 1
- 60-69 years: 0-4.5 ng/mL for whites and African-Americans, 0-4.0 ng/mL for Asian-Americans 1
- 70-79 years: 0-6.5 ng/mL for whites, 0-5.5 ng/mL for African-Americans, 0-5.0 ng/mL for Asian-Americans 1

The risk of prostate cancer increases with higher PSA levels PSA 0-2.0 ng/mL: approximately 10% risk of prostate cancer 3
- PSA 2.0-4.0 ng/mL: 15-25% risk of prostate cancer 3
- PSA 4.0-10.0 ng/mL: 17-32% risk of prostate cancer 3
- PSA >10.0 ng/mL: 43-65% risk of prostate cancer 1
A continuum of prostate cancer risk exists even at traditionally low PSA values, with cancer detection rates of 6.6% at PSA ≤0.5 ng/mL, increasing to 26.9% at PSA 3.1-4.0 ng/mL 1
High-grade prostate cancers (Gleason score ≥7) are found across all PSA ranges, with prevalence increasing from 10-12% at lower PSA levels to 25% at PSA 3.1-4.0 ng/mL 1

Digital rectal examination (DRE) should be performed in men with elevated PSA to assess for prostate abnormalities 5, 3
Prostate biopsy is typically recommended for:
- PSA >4.0 ng/mL with normal DRE 2, 1
- Abnormal DRE regardless of PSA level 5
- PSA velocity >0.75 ng/mL/year over 2 years 2
Standard prostate biopsy should include at least 8-12 cores targeting the peripheral zone of the prostate 1
Extended biopsy schemes have been proven to identify more cancer at initial biopsy compared to sextant biopsies, decreasing the false negative rate from 20% to 5% 1

5α-reductase inhibitors (finasteride, dutasteride) can reduce PSA levels by approximately 50% after 6-12 months of therapy 3
Men receiving testosterone replacement therapy require careful PSA monitoring:
- Baseline PSA should be obtained before starting therapy 2
- Follow-up PSA testing should be performed every 3-6 months for the first year and annually thereafter 2
- Prostate biopsy should be considered if PSA rises above 4.0 ng/mL or increases by more than 1.0 ng/mL in any year 2